Citi analyst Daniel Grosslight lowered the firm’s price target on Evolent Health (EVH) to $21 from $33 and keeps a Buy rating on the shares. The analyst updated health technology models post the Q3 reports.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH: